News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
GlaxoSmithKline to Pay $750 Million In Adulterated Drugs Case
October 27, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BOSTON (Reuters) - GlaxoSmithKline Plc has agreed to pay $750 million and plead guilty to manufacturing and distributing adulterated drugs from a now closed plant in Puerto Rico, the U.S. Justice Department said on Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
Legal
GlaxoSmithKline
MORE ON THIS TOPIC
Policy
FDA Policy Tracker 2026: One-Trial Drug Applications, Guidelines for Personalized Therapies
February 27, 2026
·
7 min read
·
Heather McKenzie
Drug pricing
Trump Calls on Congress To Codify Most Favored Nation Drug Pricing in SOTU
February 25, 2026
·
2 min read
·
Annalee Armstrong
Vaccines
Postponed ACIP Meeting Rescheduled for Mid-March
February 25, 2026
·
3 min read
·
Tristan Manalac
Rare disease
FDA’s Bespoke Pathway To Focus on Gene Editing and RNA-Based Treatments for Rare Diseases
February 23, 2026
·
3 min read
·
Nick Paul Taylor
